Please login to the form below
medicines use
This page shows the latest medicines use news and features for those working in and with pharma, biotech and healthcare.
NHS earmarks £340m for new medicines fund to fast-track ‘innovative’ treatments
The proposed Innovative Medicines Fund is an extension of the existing Cancer Drugs Fund. ... NHS England has announced a new ‘Innovative Medicines Fund’ worth £340m to fast-track access to new treatments, including ‘cutting-edge’ gene therapies.
Latest news
-
Roche reports strong diagnostics sales in Q1 as demand for COVID-19 tests continues
Overall, Roche noted that the pandemic continued to negatively impact areas of its business, particularly for medicines which require regular hospital visits. ... Additional sales of Actemra/RoActemra, which are being used to treat COVID-19, are up by 22%
-
AZ forecasts growth in 2021 after revenues surge in Q4
However, AZ did report that the pandemic had a significant impact on certain medicines, including sales of asthma/COPD treatment Pulmicort (budesonide) in China and some decreased use of infused/injectable ... medicines such as Imfinzi and monoclonal
-
FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
Xeljanz is approved in the US for use in adults with rheumatoid arthritis (RA) who have not responded well to methotrexate treatment. ... Providing information on the safe and effective use of our medicines is imperative,” said Tamas Koncz, chief
-
FDA experts back safety and efficacy of Moderna’s COVID-19 vaccine
Last week, the FDA approved Pfizer/BioNTech’s mRNA-based COVID-19 vaccine BNT162b2, granting it a conditional approval for emergency use in the US. ... Moderna's mRNA-1273 vaccine is also under review by the European Medicines Agency (EMA) for
-
EMA to support real-world monitoring of COVID-19 treatments/vaccines
New infrastructure will support real-world studies. The European Medicines Agency (EMA) has set up new infrastructure to support the use of real-world monitoring of potential treatments and vaccines for ... Another contract, agreed in June, saw the EMA
Roche reports strong diagnostics sales in Q1 as demand for COVID-19 tests continues
AZ forecasts growth in 2021 after revenues surge in Q4
FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
FDA experts back safety and efficacy of Moderna’s COVID-19 vaccine
EMA to support real-world monitoring of COVID-19 treatments/vaccines
More from news
Approximately 0 fully matching, plus 268 partially matching documents found.
Latest Intelligence
-
Setting up for success in a post-Brexit, post-pandemic Britain
Similarly, long-term challenges around the licensing of medicines for use in the UK, as well as the expected additional workload and cost that this will entail for industry, on top ... With three COVID-19 vaccines approved for use in the UK at the time
-
Growing evidence supports the important role of biosimilars in healthcare
Access to healthcare, including affordable medicines, remains a top concern across the US. ... This can help expand options for chronically ill patients and allow greater use of biologic medicines by providing more affordable access to individuals who,
-
Switzerland: a life sciences hub
The FDA has just granted Roche emergency use authorisation (EUA) for its new test to detect the virus that causes the coronavirus. ... Secondly, the revised Patents Act encourages the development of safe medicinal products for paediatric use.
-
The global antibiotic crisis: a 2020 perspective
drugs on a trial basis – de-linking the valuation and reward payments from the medicines’ usage. ... by 2024. The plan also supports increased use of a ‘precision medicines’ approach increasing the percentage of prescriptions informed by
-
Keeping up the fight against HIV and using the lessons to tackle other threats
of medicines to use. ... We make sure the science is understood and we use that feedback to make sure our medicines are available and used in the right way.
Setting up for success in a post-Brexit, post-pandemic Britain
Growing evidence supports the important role of biosimilars in healthcare
Switzerland: a life sciences hub
The global antibiotic crisis: a 2020 perspective
Keeping up the fight against HIV and using the lessons to tackle other threats
More from intelligence
Approximately 1 fully matching, plus 40 partially matching documents found.
Latest appointments
-
New hires at Bayer, Eisai and Accord Healthcare
Prior to joining Accord, Grosso held a number of senior public and commercial roles, including the role of principal medicines management pharmacist at UCL Hospitals. ... Grosso is also a registered pharmacist, and has a long-standing interest in the
-
ABPI Scotland appoints Sandra Auld as director
the access to and use of new and innovative medicines for Scottish patients. . ... and innovative medicines.”.
-
EFPIA's Richard Torbett to move to the ABPI
team. “His experience in both government and the pharmaceutical industry will prove invaluable when addressing the issues of access and use of new medicines in the NHS and in leading discussions
-
EAHP elects Joan Peppard as president
As president of the EAHP, Peppard will look to advance the organisation's mission to develop hospital pharmacy in order to promote the best and safest use of medicines and medical
-
ABPI appoints value and access manager
Rowland will work on a range of projects to improve patient access to innovative medicines, in line with the ABPI's strategic objectives around health technology assessment and market access. ... greater use of newer medicines,” added Catchpole.
New hires at Bayer, Eisai and Accord Healthcare
ABPI Scotland appoints Sandra Auld as director
EFPIA's Richard Torbett to move to the ABPI
EAHP elects Joan Peppard as president
ABPI appoints value and access manager
More from appointments
Approximately 0 fully matching, plus 10 partially matching documents found.
Latest from PMHub
-
What do NHS changes and the Life Sciences Vision mean for medicines?
But what do they mean for medicines? In his latest blog, Hanover Health’s Andrew Harrison argues that there is a need for a renewed value story for medicines in the ... A government review in 2005 noted the low and slow use of medicines in the NHS, and
-
Let's be ambitious for patients and life sciences investment in Global Britain
“Take up of new medicines in the UK continues to be slow by international standards”. ... Yet with the sector seen as crucial to economic regeneration post-Brexit and post-pandemic, the slower use of innovative medicines in the UK is a drag anchor on
-
World Ovarian Cancer Day: Current treatments and future hopes for ovarian cancer
Targeted therapies for ovarian cancer. In 2011, the European Medicines Agency (EMA) approved the use of targeted therapies, including an anti-angiogenic treatment alongside chemotherapy to increase the effectiveness of treatment ... Zejula. Available at:
-
NHS medicines optimisation milestone
by 2020/21 if the NHS embraces the use of best value biological medicines in a proactive, systematic and safe way’. ... The best biologics agenda and pharma. In line with the Commissioning Framework for Biological Medicines, NHS England, NHS
-
Patient Engagement and Experience Conference, 16-17 May
The conference brings together HCPs, patients, payers, government, pharma and industry under one roof to focus on patients’ engagement and experience of their treatment to improve the real-world use of ... medicines.Speaking at the conference .
What do NHS changes and the Life Sciences Vision mean for medicines?
Let's be ambitious for patients and life sciences investment in Global Britain
More from PMHub
Approximately 0 fully matching, plus 12 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Embattled Biogen talks up Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- bluebird bio gears up for split
- EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
- Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost
- Accelerating Drug Development Timelines with Big Data Analytics
- A Lucid Group Thirsty Thursday Special: Beautiful Rejects
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US orders 1.4 million more doses of Regeneron antibody cocktail
- Taking centre stage: the role of behaviour change initiatives in the management of long-term conditions
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Future of MHRA uncertain amid Brexit-fuelled shake up
- Lilly to target difficult-to-treat disease through tie-up with Lycia
- Sanofi/Regeneron bag first approval for Actemra rival sarilumab
- Lucid Group celebrates a double win at Communiqué 2021
PMHub
Mednet Group
Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...
Latest intelligence
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
- How to pick the perfect training program for your healthcare professionals
- You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...
